Back to DM DME Capital Management, LP

ROIVROIV

Showing 8 of 10 quarters

Position history for DMDME Capital Management, LP's holdings in Roivant Sciences Ltd.

Yes. DME Capital Management holds 2,152,669 shares of ROIV (Roivant Sciences), worth $76.2M, as of its Q2 2026 13F filing. The share count is unchanged from Q1 2026. DME Capital Management has held ROIV in every 13F on record since Q1 2024, 10 quarterly filings. ROIV is 1.9% of DME Capital Management's reported 13F portfolio.

Current Value

$76.2M

Current Shares

2.2M

Total Value Change

+$14.9M

Total Shares Change

-3.2M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Unchanged
2.2M
0.0%
$76.2M1.9%$35.39
0
2026-Q1
Increased
2.2M
+4.0%
$59.6M1.9%$27.70
49
2025-Q4
Decreased
2.1M
-9.1%
$44.9M1.6%$21.70
0
2025-Q3
Decreased
2.3M
-50.0%
$34.4M1.4%$15.13
0
2025-Q2
Decreased
4.6M
-16.4%
$51.3M2.2%$11.27
0
2025-Q1
Increased
5.4M
+3.2%
$54.9M2.8%$10.09
53
2024-Q4
Decreased
5.3M
-0.7%
$62.4M3.2%$11.83
0
2024-Q3
Increased
5.3M
+10.3%
$61.3M2.5%$11.54
57

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used